ARGENX SE (ARGX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
Research Workspace
Put ARGX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisModerate volatility — typically moves about 1% a day.
View RiskNot enough reads yet
Argenx needs its 2027 U.S. product launches to materialize. The company plans up to five new launches next year. Recent Phase 3 results for myositis support this pipeline. The stock trades at a 19% discount to peer multiples. This gap suggests the market is not fully pricing in growth. A discontinued Sjögren's disease trial is a specific pipeline risk. Our model puts the next-quarter miss probability near 26%. Peer multiples imply a price about 19% above where it trades. This read is provisional.
Trailing returns as of 2026-11-05. ARGX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 23 analysts currently covering ARGX (as of Nov 2026).
Based on 15 Wall Street analysts offering 12-month price targets for ARGX in the last 4 months.
Continue this research
Compare ARGX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ARGX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ARGX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
2026 spending outlook and plans for up to five 2027 U.S. launches provide meaningful forward operating and pipeline signals.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-05. EPS is implied from price ÷ P/E. Not investment advice.
Current $894.77
The last 12 months of price, then the range of analyst 12-month targets from today’s $894.77.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Quarterly operating profit missed expectations despite stronger Vyvgart sales, a modest execution concern.

Positive Phase 3 results materially advance the myositis program toward potential approval and commercialization.

Positive analyst rating supports product potential.

Analyst upgrade supports positive sentiment on valuation.
Discontinuation of a key trial undermines product pipeline.

Upgrade reflects positive sales outlook for Vyvgart.

Successful trial supports regulatory approval for product.
